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Mechanisms underlying hypertensive target organ damage (TOD) are not completely understood. The pathophysiological role of
mitochondrial oxidative stress, resulting from mitochondrial dysfunction, in development of TOD is unclear. The stroke-prone
spontaneously hypertensive rat (SHRSP) is a suitable model of human hypertension and of its vascular consequences. Pathogenesis
of TOD in SHRSP is multifactorial, being determined by high blood pressure levels, high salt/low potassium diet, and genetic
factors. Accumulating evidence points to a key role of mitochondrial dysfunction in increased susceptibility to TOD development
of SHRSP. Mitochondrial abnormalities were described in both heart and brain of SHRSP. Pharmacological compounds able to
protect mitochondrial function exerted a significant protective effect on TOD development, independently of blood pressure
levels. Through our research efforts, we discovered that two genes encoding mitochondrial proteins, one (Ndufc2) involved in
OXPHOS complex I assembly and activity and the second one (UCP2) involved in clearance ofmitochondrial ROS, are responsible,
when dysregulated, for vascular damage in SHRSP. The suitability of SHRSP as a model of human disease represents a promising
background for future translation of the experimental findings to human hypertension. Novel therapeutic strategies toward
mitochondrial molecular targets may become a valuable tool for prevention and treatment of TOD in human hypertension.
1. Introduction
It has been clearly understood that the complexity of the
etiopathogenetic basis of human hypertension extends also
to the etiopathogenesis of the related TOD [1]. An interplay
of several environmental and genetic factors, not excluding
the epigenetic regulation, modulates susceptibility to TOD
in hypertensive patients. In order to achieve an optimal
control of the vascular consequences related to high BP, we
need to dissect out the single players and to understand
the underlying mechanistic pathways. Several efforts have
been performed over the last two decades to identify the
most relevant determinants of TOD in hypertensive animal
models. Among the latter, the SHRSP represents a suitable
experimental tool.
The SHRSP was established from the SHR 40 years ago
based on its higher susceptibility to develop spontaneous
cerebrovascular accidents [2]. It develops a severe form
of hypertension and shows a shorter lifespan (about one
year), as compared to the stroke-resistant SHR (SHRSR)
[3, 4]. One-year follow-up of both strains maintained under
regular dietary feeding revealed increased occurrence of
renal, cerebrovascular, and cardiac damage in SHRSP as
compared to the SHRSR in association with higher BP levels
[4]. Interestingly, predisposition to stroke is accelerated in
the SHRSP by feeding with a high salt/low potassium dietary
regimen (Japanese style diet) and it is preceded by renal
damage occurrence [5, 6]. Notably, the SHRSR does not show
either renal damage or the stroke phenotype when exposed
to the same high salt diet despite BP levels comparable to
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those of SHRSP, thus indicating a peculiar susceptibility of
the SHRSP strain to high salt induced vascular damage [7, 8].
The SHRSP can be considered a suitable animal model
for studies of human hypertension since it shares several
features in common with the human pathological condition.
In particular, high BP levels, dietary salt excess, and reduced
potassium intake favour cardiovascular damage develop-
ment, such as cerebrovascular and renal disease, in both
SHRSP and in humans [9].
The type of stroke detected in SHRSP is predominantly
ischemic (80%) and to a lesser extent hemorrhagic (20%),
similarly to humans. Histopathological studies of the brain
reveal most of the key signs of small vessel disease: segmental
wall damage, depletion of smooth myocytes, accumulation
of fibrous tissue, wall thickening, luminal narrowing, blood
brain barrier leakage, and perivascular oedema. These alter-
ations can be summarized as a fibrinoid vascular lesion
caused by a degenerative-infiltrative-proliferative disease
process which affects short segments of penetrating arterioles
in multiple, wide scattered foci [10, 11].
2. Pathophysiological Studies of
TOD in SHRSP
The pathophysiological evidence obtained over the years in
the SHRSP supports a major role of higher BP levels in
producing increased susceptibility to TOD. On the other
hand, as previously mentioned, additional causative factors
appear to be involved, being triggered by high salt/low
potassium dietary feeding. Previous studies exploring the
mechanistic aspects of increased vascular damage in high salt
fed SHRSP found implications of the RAAS abnormalities
[5], of increased oxidative stress, as compared to both WKY
and SHRSR strains [12–14], of reducedNO bioavailability, the
latter being the result of NO scavenging by the increased lev-
els of anion superoxide [15], of increased local and systemic
inflammation with accumulation of acute-phase proteins in
body fluids [16].
In fact, therapeutic strategies aimed at counteracting the
RAAS activation with ACEI and ARB turned out to be more
beneficial than beta-blocker and calcium antagonist drugs
despite comparable BP lowering effect [17–19]. Interestingly, a
high potassium diet improved life survival, independently of
BP levels reduction [20]. Moreover, interventional strategies
able to counteract the increased rate of oxidative stress
and of systemic inflammation were able to prevent the
development of TOD and to increase SHRSP survival [19, 21–
23]. Increasing vascular NO levels through a gene therapy
approach restored endothelial function [24].
Thus, although hypertension remained a major permis-
sive factor, the above-mentioned evidence indicated that
hypertensive TODhad a complexmultifactorial pathogenesis
in this animal model. In particular, the evidence that SHRSP
developed strokewhereas SHRSR did not upon the same high
salt dietary feeding, despite similar BP levels, prompted us
several years ago to search for BP independent contributing
factors. In fact, the existence of hypertension independent
etiopathogenetic determinants underlying stroke in this
animal model was convincingly demonstrated through the
genetic approach [7].
3. Genetic Studies of TOD in SHRSP
The availability of an inbred genetically homogenous animal
model represents a great challenge for the discovery of genes
contributing to both hypertension and to the related vascular
damage [25]. First of all, a specific genetic background was
shown to determine development of hypertension in SHRSP
[26–29]. Subsequently, in order to dissect out genes con-
tributing to stroke in hypertension, few research efforts were
performed through a genetic linkage analysis approach in F2-
hybrid cohorts from either SHRSR/SHRSP or SHRSP/WKY
intercrosses [7, 30, 31]. The results of these studies revealed
the existence of genes playing a direct contributory role in the
stroke phenotype occurrence mapping within different areas
(QTL) of the rat genome.Moreover, the existence of genes for
renal damage was revealed in SHRSP [32].
Although no specific gene predisposing to either hyper-
tension or its vascular consequences has been precisely
identified yet in SHRSP, strong evidence has been collected
over the last few years with regard to few candidate genes
(mapping within the identified stroke QTLs) and their
encoded proteins involved in both stroke and renal damage
development.
In this regard, an altered sequence and regulation of the
atrial natriuretic peptide gene, mapping at the lod score peak
of a QTL on rat chromosome 5, STR2, in the SHRSR/SHRSP
F2-hybrid cohort [7], were found in SHRSP, a finding later
on translated to humans, as described in detail in previous
review articles [35, 36]. Interesting observations were also
reported with regard to Stim1 gene and the response to stress
in SHRSP [34]. Additional genes that emerged as putative
candidate for both brain and renal vascular damage in the
SHRSP are shown in Table 1 [33, 37–39].
In the present paper, wewill discuss the available evidence
related to genes encodingmitochondrial proteins, underlying
both stroke and renal damage development in SHRSP, that
were discovered within STR1.
4. In the Search for Stroke Genes Mapping
within the Stroke QTL STR1 in SHRSP
The major finding of the linkage analysis performed in the
SHRSR/SHRSP F2-hybrid cohort was the identification of
STR1, a QTL included between Klk and Mt1pa markers,
extending for an overall 80 cM length and showing a 6.7 lod
score peak in correspondence with the anonymous marker
D1Mit3. Based on our studies, STR1 contributed to 20% of
the overall stroke phenotype variance [7]. Notably, its stroke
contributory effect was confirmed by congenic experimenta-
tion [8]. In fact, congenic lines were prepared by performing
several backcrosses of SHRSP with SHRSR [8]. As a result,
the congenic animals carrying the STR1/QTL in the SHRSP
configuration within the SHRSR genomic background had
increased stroke occurrence, with respect to the SHRSR
parental strain of origin. Vice versa, the congenic animals
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Table 1: Genes identified in SHRSP in relation to increased susceptibility to vascular damage.
Gene name Experimental context Reference
Ndufc2 Salt loading (brain) [13]
UCP2 Salt loading (kidneys) [14]
Mit HMG-CoA synthase Standard chow (kidneys) [33]
Nrf2 Standard chow (arteries and VSMC) [12]
Agt Standard chow (adrenal glands, kidneys, brain) [38
Stim1 Exaggerated sympathetic response to stress [34]
Atrial natriureticpeptide Salt loading (brain) [35, 36]
MMP14 Gene expression analysis of brain SVD [37]
Gnai1 Gene expression analysis of brain SVD [39
Vasopressin Gene expression analysis of brain SVD [37]
Albumin Gene expression analysis of brain SVD [37]
NO receptor Gene expression analysis of brain SVD [37]
Gucy1a3 Gene expression analysis of brain SVD [37]
Rps9 Gene expression analysis of brain SVD [37]
Edg1 Salt loading (kidneys) [38]
Vcam1 Salt loading (kidneys) [38]
Mit HMG-CoA: mitochondrial 3-hydroxy-3-methylglutaryl-coenzyme A; Gnai1: guanine nucleotide binding protein alpha inhibitor 1; Nrf2: nuclear factor
erythroid 2-related factor; Agt: angiotensinogen; Stim1: stromal interactionmolecule 1; NO: nitric oxide;MMP14:metalloproteinase 14; Rps9: ribosomal protein
S9; Gucy1a3: guanylate cyclase 1, soluble, alpha 3; Edg1: endothelial differentiation gene receptor 1; Vcam1: vascular cell adhesion molecule 1; SVD: small vessel
disease.
carrying the STR1/QTL in the SHRSR configuration within
the SHRSP genomic background showed decreased stroke
occurrence as compared to the SHRSP parental strain of
origin [8]. These results clearly indicated that the STR1/QTL
contained one or more genes directly contributing to stroke
predisposition in the animal model. In fact, subsequent stud-
ies, addressed to identify the potential genetic determinants
of stroke contained within the STR1/QTL, revealed novel
mechanisms contributing to vascular damage.
In particular, the mitochondrial dysfunction was discov-
ered as a crucial mechanism underlying stroke development
in SHRSP.
5. Mitochondria as a Source of ROS and of
Vascular Damage in Hypertension
ROS behave as an important intracellular and intercellular
second messenger that modulate several downstream signal-
ing molecules leading to vascular smooth muscle cell growth
and migration, expression of proinflammatory mediators,
and remodeling of extracellular matrix [40]. In addition,
oxidative stress increases intracellular free calcium concen-
tration, a major determinant of vascular reactivity [41]. The
most relevant sources of ROS with respect to vascular dis-
ease and hypertension are NADPH oxidase; NOS; xanthine
oxidase; and mitochondria. A feedforward interplay exists
between these ROS sources [42]. For instance, activation of
NADPH oxidases by angiotensin II increases mitochondrial
superoxide production [43].
Mitochondria represent a major source of energy for cells
and their function is fundamental for life of all organisms
[44]. They mediate oxidative phosphorylation via electrons
transfer through multimeric complexes to produce ATP.
Electrons are donated from NADH to complex I and then to
other components of the chain in order to reduce molecular
oxygen (O
2
) to form H
2
O. Flow of electrons through the
OXPHOS chain is accompanied by pumping of protons
across the mitochondrial inner membrane, thus creating a
transmembrane electrochemical gradient. Complex I, known
asNADH:ubiquinone oxidoreductase, is the largest of the five
OXPHOS complexes and it is composed of 45 subunits (seven
encoded by mitochondrial DNA and 38 encoded by nuclear
DNA). Complex I leaks electrons in the intermembrane
space to generate mitochondrial anion superoxide (O
2
−).The
reentry of protons into the matrix is used by complex V to
synthetize ATP from ADP [44]. Thus, complex I contributes
to about 40% of the proton motive force that drives ATP
synthesis by ATP synthase and, along with complex III, is the
major source of O
2
− production [44].
Under physiological condition, ROS are produced as a
byproduct of the respiratory chain due to 1-electron reduction
of O
2
to O
2
− [44]. Mitochondria are the major source of
cellular ROS and they also contain antioxidant mechanisms
such asmitochondrial matrix enzymemanganese superoxide
dismutase, glutathione peroxidase, and peroxiredoxins 3 and
5 [45]. Accumulation of ROS, as a result of an imbalance
between production and clearance, leads to damage of mito-
chondrial proteins of lipids and of DNA with consequent
alteration of the mitochondrial function and further increase
of ROS.Moreover,mitochondrial superoxide stimulates cyto-
plasmic NADPH oxidase activity in endothelial cells and
therefore further contributes to development of endothelial
oxidative stress [46].
It is becoming more and more clear that mitochon-
drial dysfunction causing excessive ROS production may
contribute to the pathogenesis of common cardiovascular
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diseases [47]. Notably, mitochondria may be involved in the
genesis of hypertension and hypertension itself may promote
mitochondrial dysfunction in the brain, heart, vasculature,
and kidneys [48].
Themechanisms underlying the increasedmitochondrial
oxidative stress which has been described in the cardiovas-
cular system of several models of hypertension are multiple
[48]. Through a crosstalk interaction between NADPH oxi-
dases andmitochondria, the stimulation of vascular NADPH
oxidases, for instance, by angiotensin II, increases mito-
chondrial oxidative stress [48]. Notably, excess salt, through
ROS produced by angiotensin II-activated NADPH oxidase,
caused cerebral neuronal apoptosis and inflammation as
well as stroke in SHRSP [49]. A mechanosensitive blood
pressure-induced mitochondrial ROS production has been
shown to exacerbate vascular oxidative stress in hyperten-
sion [50]. In addition to pressure, a shear stress-induced
mitochondrial ROS is considered an important mechanism
at the endothelial level [48, 51]. Along with the above-
mentioned evidence, an imbalance between ROS production
and the mitochondrial antioxidant systems contributes to
increased oxidative stress in hypertension [48]. Increased
mitochondrial oxidative stress may sustain hypertension as
suggested by evidence that activation of the RAAS stimulates
mitochondrial redox signaling pathways and leads to aug-
mented neuronal firing that exerts a key role in the central
regulation of BP [52].
Mitochondrial dysfunction may also contribute to pro-
moting hypertensive TOD. In this regard, an assembly defect
in complex I and in complex V of the OXPHOS in SHR
brain mitochondria, causing a decreased ATP production
and cell energy deficiency, was previously described [53].
Evidence of cardiac mitochondrial damage was documented
in experimental models of hypertension, including the SHR
[54, 55]. Mitochondrial abnormalities were described in the
heart of SHR [56] and in the kidneys of both renovascular and
essential hypertensive animal models [57, 58].
The SHRSP provides key insights into the contribution
of mitochondrial dysfunction in the pathogenesis of vascular
damage associated with hypertension. This concept was
hypothesized in SHRSP for the first time several years ago,
based on evidence of a significant increase of mitochondria
in cardiomyocytes of lacidipine treated SHRSP [59]. The
presence of alterations in mitochondrial DNA and enzyme
activities was described in the hypertrophied heart of SHRSP
[60]. Mitochondrial abnormalities were also related to the
brain damage following middle cerebral artery occlusion in
SHRSP [61].
Of note, treatment with S 35171, a compound able
to protect mitochondrial function by increasing the inner
antioxidant systems, was shown to delay and even to prevent
brain damage in high salt fed SHRSP, as a result of protection
from systemic processes linked tomitochondria and involved
in brain damage [62]. Notably, this compound had only a
modest, not significant effect on BP levels [62]. Furthermore,
a therapeutic strategy targeted at the mitochondria oxidative
stress throughmitoQ10 administration (either alone or added
to losartan) was shown to exert beneficial effects on BP levels
reduction and, particularly, on protection from the associated
vascular and cardiac damage [63, 64]. Interestingly, mitoQ10,
which is specifically directed toward mitochondrial oxidative
stress, attenuated the hypertension development but it did not
prevent it. Parallel in vitro studies showed dose-dependent
inhibition of hypertrophy in cardiomyocytes exposed to
mitoQ10 indicating a direct prohypertrophic effect of mito-
chondrial ROS [63].
Moreover, the significant protective effect described with
fenofibrate on both renal and cerebral damage in salt loaded
SHRSP [65]may bemediated by its PPAR𝛼 agonist action and
the consequent stimulation of UCP2 expression levels [66].
6. Ndufc2 as a Stroke Susceptibility Gene
within STR1
Through amicroarray differential expression analysis, includ-
ing all sequences mapping inside STR1, we discovered the
gene encoding the mitochondrial protein Ndufc2 (a subunit
of the OXPHOS complex I, encoded by nuclear DNA) as a
sequence significantly downregulated by high salt diet only
in the brain of SHRSP as compared to the SHRSR [13]. This
evidence associated with signs of mitochondrial dysfunction,
such as reduced ATP and increased ROS levels. Furthermore,
we discovered that the Ndufc2 silencing in vascular cells
led to a significant impairment of complex I assembly, to
a reduction of mitochondrial membrane potential and of
ATP synthesis, with consequent marked accumulation of
ROS, increased inflammation, increased cell necrosis, and
reduced cell viability [13]. In vivo, a heterozygous Ndufc2-ko
rat model, obtained from the parental SHRSR strain, showed
a deficient complex I assembly and, more importantly, once
fed with the Japanese style diet, developed renal damage
followed by stroke occurrence, similarly to what occurs in
SHRSP [13]. No differences in BP levels were detected in the
Ndufc2-komodel as compared to its strain of origin under the
same high salt diet, thus underscoring a direct contributory
role of mitochondrial dysfunction in the development of
vascular damage. As a consequence of single gene effect,
the percentage of stroke events did not go above 40%. The
identification of a marker of the human gene, associated with
a significant NDUFC2 defective expression in carriers and
with early-onset ischemic stroke occurrence [13], supports
the hypothesis that reduced NDUFC2 expression could
contribute to increased stroke susceptibility also in humans.
Function of the Ndufc2 is starting to be understood [67].
The observations obtained in the SHRSP reveal a key role of
Ndufc2 in complex I assembly, a critical step for an appropri-
ate complex I activity and for the whole OXPHOS function
(Figure 1). Of note, these findings parallel and reinforce previ-
ous data obtained in type 2 diabetes mellitus [68]. Moreover,
NDUFC2 appears downregulated in skeletal muscle cells of
subjects affected by insulin resistance [69] and it is associated
with insulin secretion in vivo [70]. Ndufc2 expression is
induced under Bendavia treatment, a novel molecule able to
counteract mitochondrial dysfunction, in the noninfarcted
border zone within the rat heart, underscoring a key role of
a regular complex I activity in ischemic heart disease [71].
NDUFC2 may also represent a novel oncogene involved in
breast cancer and intestinal adenocarcinoma, predicting poor
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Figure 1: Schematic representation of the electron transport chain OXPHOS within the inner mitochondrial membrane. Complex I is
highlighted to underscore its major relevance as a determinant of excessive mitochondrial ROS production when it becomes dysfunctional.
In particular, lack of Ndufc2 subunit of complex I is highlighted to indicate that it leads to disassembly and dysfunction of the complex.
As a result, NADH cannot be converted to NAD+, with consequent reduction of the flux of protons into the matrix, significant decrease of
mitochondrial membrane potential, increase of anion superoxide, and reduction of ATP synthesis. The resulting cellular and tissue damage
can contribute to target organ damage development in hypertension.
prognosis [72, 73]. Interestingly, an epigenetic regulationmay
contribute to modulating Ndufc2 expression. In fact, this
gene has been described, but not yet experimentally proven,
as a predicted target of miRNA34a. The latter is a small non-
coding RNA exerting a significant impact on mitochondrial
function and on blood brain barrier integrity [74].
Whereas the above-mentioned evidence highlights the
role of NDUFC2 as a novel gene for human diseases, the
results obtained in SHRSP bring up to our attention for
the first time the importance of an adequate mitochondrial
function, through a regular complex I assembly and activity,
in order to maintain the vascular health status and to avoid
TOD development in hypertension. Of note, complex I
mediated production of mitochondrial O
2
− has been impli-
cated so far in ischemic preconditioning, in aging and, only
indirectly, in hypertension [75]. Deficiency of complex I
causes neurotoxicity [76].
7. UCP2 as a Suitable Candidate Gene for
Renal Damage in SHRSP
Identification of UCP2 mapping nearby the load score peak
of STR1 revealed unexpected interesting implications for
the renal injury phenotype of SHRSP. UCP2, belonging to
the uncoupling proteins family, is located within the inner
mitochondrial membrane where it carries negative ions (H+)
and it dissipates the mitochondrial proton gradient that con-
tributes to anion superoxide formation by reverse electron
flow from complex II to complex I [77]. Its dysregulation
has been associated with either high salt or obesity related
vascular dysfunction [78–80]. On the other hand, UCP2
overexpression is able to restore a normal vascular function
[81, 82]. It has been suggested that an impairment of the
protective role of UCP2 may also contribute to hypertension
development [83]. Interestingly, mice overexpressing UCP2
show a longer lifespan [84].
We discovered a differential regulation of UCP2 expres-
sion levels, upon the stroke-permissive high salt diet, in
kidneys of SHRSP versus SHRSR with evidence of reduced
expression in stroke-prone and increased expression in
stroke-resistant rats [14]. We also provided evidence that
knocking out UCP2 gene in renal cells led to increased
oxidative stress, reduced ATP synthesis, and increased cell
necrosis [14]. Our experimental findings are consistent with
previous evidence showing an involvement of UCP2 in
human kidney disease [85–87].
Interestingly, the stimulation of renal UCP2 expression,
by administration of a vegetable extract obtained from
Brassica oleracea sprouts, was able to counteract the high salt
diet induced renal damage of SHRSP, independently of BP
levels [88]. The key role of UCP2 stimulation in mediating
the positive effects of Brassica oleracea sprouts extract was
reinforced by evidence that parallel blockade with a selective
inhibitor of PPAR𝛼, a family of nuclear transcriptional factor
receptors that regulate several genes includingUCP2 [66], did
not allow any further protection from renal damage in high
salt fed SHRSP [88].
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Figure 2: Schematic representation of the effects of UCP2 down-
regulation within the inner mitochondrial membrane. As a con-
sequence of the reduced UCP2 function, a lower number of
protons are shifted into the matrix with a consequent increase of
reactive oxygen species and dysfunction of the wholeOXPHOSwith
decreased ATP synthesis and cellular damage.
A similar striking differential modulation, that is sup-
pression of UCP2 gene and protein expression, was found
in relation to both hypertension and aging in the brain,
heart, and kidneys of SHRSP but not of SHRSR [4]. Thus,
based on the reported evidence, high salt diet, high blood
pressure levels, and aging are able to turn off tissue UCP2
gene expression only in SHRSP through still unexplained
mechanisms. In this regard, an epigenetic regulation may be
involved, as suggested by evidence obtained in relation to the
kidney injury of this model [13].
Consistent with the critical role of UCP2 in clearance of
ROS, whenever UCP2 expression is decreased levels of both
oxidative stress and inflammation are remarkably increased,
and levels of ATP are decreased with consequent cellular
and tissue damage (Figure 2). Restoring UCP2 expression
levels, as observed under theBrassica oleracea sprouts extract,
appears a critical step to prevent TOD development in
hypertension [88]. Altogether, these data indicate that UCP2
plays a role in the setting of hypertensive TOD.
Of note, the beneficial cardiovascular effects of vegetable
compounds, including Brassica oleracea, were also reported
in humans [89], thus underscoring their potential useful role
as an adjuvant to conventional cardiovascular therapies. The
improvement of mitochondrial function by the vegetables
administration is oftenmediated throughUCP2 upregulation
[89].
Overall, the results of our experimental research in the
SHRSP strongly support the hypothesis that mitochondrial
dysfunction may be an important contributory pathogenetic
mechanism underlying hypertensive vascular damage, inde-
pendently of BP levels, and that the SHRSP is a suitable
animal model of mitochondrial oxidative stress-dependent
hypertensive TOD. In fact, through the discovery of two
mitochondrial proteins as key determinants of both cerebral
and renal damage, a cause-effect relationship between mito-
chondrial dysfunction and hypertensive vascular damagewas
revealed in a clear manner in the SHRSP. Of note, apart
from the two genes discussed herein, some of those listed
in Table 1 may also contribute to mitochondrial dysfunction
and to vascular damage in this animal model. Among all,
the mitochondrial HMG-CoA synthase plays an antioxidant
protective role in the kidneys [33], similarly to UCP2.
Notably, a gene-environment interaction appears criti-
cal to unmask the inherited mitochondrial dysfunction of
SHRSP. The precise mechanisms by which salt excess inter-
feres with mitochondrial function still need to be clarified.
The role of an epigenetic regulation, as discussed for both
Ndufc2 and UCP2, cannot be excluded.
Apart from the positive lessons learned from this animal
model, some drawbacks should also be outlined. First of all,
the complex nature of human hypertensive vascular damage
certainly relies on additional genetic factors that remained
undiscovered in SHRSP due either to technical limitations of
the methodological approaches or to limitations inherent in
the model. For instance, no information could be obtained
through the use of this model on the role of mitochondrial
DNA variants on oxidative vascular damage in hypertension.
In this regard, it is known that mitochondrial DNA plays a
role in distinct pathological contexts [90]. Its pathogenic role
in hypertensive TOD still needs to be clarified. Moreover, by
specifically studying mitochondrial dysfunction in a peculiar
model of stroke and renal damage associated with hyper-
tension, other relevant pathogenetic contributions of this
molecular mechanism in cardiovascular diseases (ischemic
heart disease, left ventricular hypertrophy, and metabolic
syndrome) are missed.
8. Expected Relevance of the Experimental
Findings for Human Hypertensive Disease
The consequences of a dysregulated mitochondrial function
obviously apply to each living organism through the cell
and tissue damage consequent to the increased oxidative
stress and reduced ATP production. In fact, mitochondrial
dysfunction has been already established as an important
pathogenetic determinant of common neurodegenerative
diseases in humans [91].
In contrast, current knowledge on the role of mitochon-
drial dysfunction in human hypertensive vascular damage
is still very scarce. The animal model reveals exciting new
results in this regard by highlighting the role of a complex
I subunit and of UCP2 into increased renal and cerebrovas-
cular damage. We expect to see a translation of the evidence
obtained in SHRSP to the human disease, since several
findings reported in this model often anticipated those
encountered later on in the human pathological context. For
instance, we were able to translate to humans the information
provided by SHRSP about the role of the atrial natriuretic
peptide gene as a determinant of stroke [35, 36]. The current
preliminary translation to human ischemic stroke of the
results obtained in SHRSP with regard to the contributory
role ofNdufc2 looks promising [13]. It suggests that a defective
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complex I may play a pathogenic role also in human stroke.
Larger genetic human studies will better assess this evidence.
Furthermore, evidence that UCP2 is involved in human
chronic kidney disease [92, 93], including that of hypertensive
origin [85], reinforces the implications of the experimental
findings obtained in SHRSP and underscores an important
role of this mitochondrial protein in human pathology as
well.
Future studies will better define the true pathogenetic
relevance of mitochondrial dysfunction in both animal mod-
els and human hypertensive vascular disease. It cannot be
excluded that an improvement of mitochondrial dysfunc-
tion may represent a mechanism by which available anti-
hypertensive drugs can modulate vascular oxidative stress
and exert vascular protection beyond their BP lowering
effect. In addition, novel targeted strategies, designed toward
mitochondria dependent pathogenic mechanisms [94], may
reveal a useful therapeutic tool through their ability to
improve mitochondrial function and therefore to protect
patients from TOD development in hypertension. In this
regard, the SHRSP represents a precious tool to gain insights
into themechanisms of cardiovascular actions of both old and
novel antihypertensive pharmacological agents.
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